AG Gansler: Astellas Pharma US Inc. Pays $7.3 Million to Resolve False Claims Act Allegations Related to Marketing of Antifungal Agent?
Baltimore, MD (July 25, 2014) - Attorney General Douglas F. Gansler announced today that Maryland, joined by multiple states and the federal government, has settled allegations that Astellas Pharma US, Inc. (Astellas) caused false claims to be submitted to federal and state health care programs in connection with its marketing and promotion of the drug Mycamine for pediatric use. Mycamine is a sterile, lyophilized (freeze-dried) antifungal agent that was approved only for use by adults. As part of the settlement, Astellas will pay $13,583.96 to the Maryland Medicaid program.
- Date:July 25, 2014
- Agency:Maryland Attorney General
- State Enforcement Agencies